Acorai

Cover Block

Name	Acorai
Tagline	Develops non-invasive handheld Acorai Heart Monitor using multi-sensor SAVE system and ML for heart failure pressure monitoring.
Headquarters	Helsingborg, Sweden
Founded	2019
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$9,000,000)

Links

• Website: https://acorai.com/
• LinkedIn: https://www.linkedin.com/company/acorai

The Short Version

Acorai is a Swedish medtech startup developing a handheld, non-invasive device to estimate critical cardiac pressures, aiming to reduce the need for invasive catheterization in heart failure management [TechCrunch, January 2024]. The company warrants attention for its technical validation in a large clinical study and its positioning to enter the US market pending regulatory clearance next year. Founded in 2019, Acorai has progressed from a research concept to a device with FDA Breakthrough Designation, supported by a total of approximately $9 million in grants and seed funding [Perplexity Sonar Pro, Unknown]. Its core product, the Acorai Heart Monitor, uses a proprietary multi-sensor system (SAVE) combined with machine learning to provide hemodynamic data, a method clinically tested in over 2,000 patients [Acorai, Unknown]. The business model targets hospital sales for clinician use, with a commercial launch anticipated by 2026 and US entry targeted for the second half of 2025 [TechCrunch, January 2024].

Data Accuracy: YELLOW -- Core product and funding claims are company-sourced; clinical study and FDA designation are corroborated by third-party publications. Market size and total funding figure rely on a single secondary source.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$9,000,000)

The Company in Brief

Acorai is a Swedish medical device company founded in 2019 and headquartered in Helsingborg [Perplexity Sonar Pro, Unknown]. The company was established to develop a non-invasive handheld monitor for heart failure management.

In 2023, Acorai secured a €2.3 million grant from the European Commission [Acorai, Unknown]. This was followed in January 2024 by a $4 million seed round led by Solardis Health Ventures [TechCrunch, January 2024]. The total capital raised across these and other undisclosed rounds is reported at approximately $9 million [Perplexity Sonar Pro, Unknown]. A key regulatory milestone was receiving FDA Breakthrough Device Designation for its Heart Monitor [Medical Device Network, Unknown].

Data Accuracy: YELLOW -- Key dates and amounts rely on a single primary source (TechCrunch) and company blog posts; total funding figure is not independently corroborated.

What They Have Built

The core of Acorai's proposition is a hardware and software system designed to replace an invasive diagnostic procedure with a brief, non-invasive measurement. The Acorai Heart Monitor is a handheld device that uses its patented SAVE Sensor System to estimate intracardiac pressures, specifically pulmonary artery pressure, by placing the unit on a patient's chest for a few minutes [Acorai] [TechCrunch, January 2024].

The SAVE system integrates four sensor modalities: seismic, acoustic, visual, and electrical, with machine learning algorithms to interpret the combined signal [Acorai]. The company states the technology has been clinically tested in over 2,000 patients [Acorai]. Its primary clinical validation effort is the ongoing CAPTURE-HF study. Enrollment for this study is complete, and positive results from a 1,600-patient cohort were presented in 2025 [Acorai News] [MedTech Innovator, 2025]. The company has received FDA Breakthrough Device Designation for the monitor [Medical Device Network].

Data Accuracy: YELLOW -- Product claims are sourced from company materials and one press article; clinical study details are from company announcements and a third-party summary.

Market Research and Opportunity

The total addressable market is anchored by a global patient population of approximately 60 million individuals living with heart failure [Perplexity Sonar Pro]. The served addressable market for Acorai's initial focus is the in-hospital workflow for suspected or confirmed heart failure patients [TechCrunch, January 2024].

Metric	Value
Global Heart Failure Patients	60 million

Data Accuracy: YELLOW -- Market size figure is from a single, unverified source; demand drivers and regulatory status are corroborated by multiple public statements.

Who Else Is Fighting for This

Acorai's competitive position is defined by its attempt to replace a gold-standard invasive procedure with a non-invasive, handheld alternative.

• Invasive procedure incumbents. The primary alternative is the right heart catheterization (RHC), an invasive procedure performed in a catheterization lab to directly measure pulmonary artery pressures.
• Non-invasive monitoring challengers. This segment includes implantable wireless pressure sensors (e.g., CardioMEMS by Abbott) and external wearable devices focused on other physiological signals.
• Adjacent diagnostic substitutes. The competitive set expands to include other tools clinicians use to assess heart failure status, such as echocardiography, blood biomarker tests (e.g., BNP), and physical exam findings.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated target and technology; no direct competitor names were captured in sources.

Opportunity

If Acorai can successfully navigate the regulatory path and establish its handheld monitor as a new standard of care in heart failure management, the prize is a central role in a multi-billion dollar global market for non-invasive hemodynamic monitoring.

Scenario	What happens	Catalyst	Why it's plausible
Standard of Care in Heart Failure Wards	The Acorai Heart Monitor becomes a routine part of the admission and monitoring protocol for heart failure patients in major hospitals, reducing catheterization volumes.	Successful completion and publication of the CAPTURE-HF study results demonstrating non-inferiority to catheterization.	The study has enrolled a large patient cohort (1,600 patients) and positive initial results were presented in 2025 [MedTech Innovator, 2025].
Expansion into Adjacent Hemodynamic Monitoring	The SAVE sensor platform is validated for monitoring pressures in other cardiac conditions (e.g., pulmonary hypertension) or in critical care settings (e.g., ICU), expanding the addressable market.	FDA clearance for the initial heart failure indication, providing a regulatory foundation for subsequent 510(k) submissions for new uses.	The multi-modal sensor approach is fundamentally designed to capture a broad range of physiological signals [Acorai].

Data Accuracy: YELLOW -- The core opportunity framing relies on company-stated clinical progress and a broad market estimate from a secondary source.

Sources

1. [TechCrunch, January 2024] Heart failure monitoring startup Acorai turns heads | https://techcrunch.com/2024/01/30/acorai-seed/
2. [Acorai] Home - Acorai | https://acorai.com/
3. [Acorai] Product - Acorai | https://acorai.com/product/
4. [Acorai] Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission | https://acorai.com/redefining-heart-failure/heart-failure-start-up-acorai-secures-e2-3m-grant-funding-from-the-european-commission/
5. [Acorai News] Heart Failure start-up, Acorai, closes oversubscribed $4m funding round | https://acorai.com/acorai-news/heart-failure-start-up-acorai-closes-oversubscribed-4m-funding-round/
6. [Medical Device Network] Acorai receives FDA Breakthrough Device Designation | https://www.medicaldevice-network.com/
7. [MedTech Innovator, 2025] ACORAI Presents Positive Results in 1,600-Patient CAPTURE-HF Study | https://medtechinnovator.org/acorai-presents-positive-results-in-1600-patient-capture-hf-study-for-its-ai-powered-non-invasive-multi-sensor-platform-for-improved-heart-failure-patient-management/